Global Cancer Biomarkers Market has accounted to USD 10.9 billion in 2016, growing at a CAGR of 12.2% from 2017 to 2024, and is expected to reach USD 27.4 billion by 2024.

Global Cancer Biomarkers Market Trends and Forecast to 2022
• By Tumor (Breast, Lung, Prostate)
• By Type (Protein & Genetic Biomarkers)
• By Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay)
• By Application (Diagnostic, Drug Discovery, Prognostic)

Visit For You’re Free Sample Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-biomarkers-market

Market Definition:
• Cancer biomarkers are the molecules secreted by a tumor or a specific response of the human body indicating the presence of cancer.
• The biomarkers enable cancer detection at an early stage and facilitate high-speed noninvasive diagnosis using various genomics and proteomics tools.
• Cancer biomarkers are used for various applications such as cancer diagnostics, drug discovery and development, prognostics, personalized medicine, and surrogate endpoints.
• Over the years, cancer biomarkers have become an integral part of research in pharmaceutical and clinical trial companies, as they help to reduce the time and cost of the drug discovery and development process.

Major Players:
• Abbott Laboratories,
• Affymetrix, Inc.,
• Illumina, Inc.,
• Qiagen N.V.,
• Roche Diagnostics Ltd.,
• Agilent Technologies Inc.,
• Quest Diagnostics Inc.,
• Merck & Co. Inc.,
• Hologic, Inc.,
• Becton Dickinson and Company
• among others.

Based on Cancer Type:
• The cancer biomarkers market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other cancers (includes melanoma, leukemia, gastric, kidney, liver, and pancreatic cancers).
• In 2015, the breast cancer segment accounted for the largest share of the global cancer biomarkers market. The largest share of this segment is mainly attributed to the high prevalence of breast cancer over the last few years, increased awareness about breast cancer diagnosis, and increasing research focus on breast cancer.
• However, the lung cancer segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment can be attributed to the rising prevalence of lung cancer and increasing research focus on lung cancer biomarkers.

Detailed Data On Report Page: https://databridgemarketresearch.com/news/product-launch/global-cancer-biomarkers-market/

About Us-
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us-
Data Bridge Market Research
US: +1-888-387-2818
Email: [email protected]
Website: https://databridgemarketresearch.com